Hikma Pharmaceuticals PLC (LON:HIK) Receives Average Recommendation of “Buy” from Brokerages

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have received an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,085.83.

A number of equities analysts have weighed in on HIK shares. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Berenberg Bank upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group raised their target price on shares of Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the company a “buy” rating in a research note on Tuesday, August 25th.

Hikma Pharmaceuticals Trading Down 0.4%

Shares of HIK stock opened at GBX 1,599 on Friday. The company has a market capitalization of £3.34 billion, a PE ratio of 8.83, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,865. The business’s fifty day moving average is GBX 1,596.47 and its 200 day moving average is GBX 1,463.06. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98.

Insider Activity at Hikma Pharmaceuticals

In related news, insider Tobias Hestler purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.